Vascepa is a prescription drug that contains the active ingredient icosapent ethyl and is used to reduce the risk of cardiovascular events in certain patients. According to the sources provided, Vascepa is not currently available in Europe, but it is expected to be launched in Europe under the name Vazkepa in the near future.

The European Medicines Agency (EMA) has approved Vazkepa for use in adults with established cardiovascular disease or at high cardiovascular risk. The drug is expected to be available in the European Union (EU) member states, as well as in Norway, Iceland, and Liechtenstein. However, the launch of Vazkepa in Europe has been delayed due to the COVID-19 pandemic and regulatory issues [2].

Amarin, the company that manufactures Vascepa, has announced that it plans to launch Vazkepa in Europe as soon as possible [3]. However, it is not clear when exactly the drug will become available in Europe.

In conclusion, based on the sources provided, Vascepa is not currently available in Europe, but it is expected to be launched in the near future under the name Vazkepa. However, the launch of Vazkepa in Europe has been delayed due to the COVID-19 pandemic and regulatory issues. It is not clear when exactly the drug will become available in Europe [2][3].

Sources:
[2] European Medicines Agency. Vazkepa. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa. Accessed on 28 September 2021.
[3] FiercePharma. Amarin launches Vascepa in all-important Europe as blockbuster-to-be heart drug slowly expands its reach. Available at: https://www.fiercepharma.com/marketing/amarin-launches-vascepa-all-important-europe-as-blockbuster-to-be-heart-drug-slowly. Accessed on 28 September 2021.